The restless legs syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs or arms for relief of uncomfortable or unpleasant sensations. Prevalence and prognostic impact of RLS on patients with heart failure (HF) remain unclear. We aimed to investigate the clinical characteristics and prognostic impact of RLS on HF patients.
H eart failure (HF) is a major cause of death among the elderly in many countries. [1] [2] [3] [4] It has been recently reported that sleep disturbance is associated with an increased risk of incident cardiovascular disease (CVD) [5] [6] [7] [8] and HF. 9, 10) Restless legs syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs or arms for relief of uncomfortable or unpleasant sensations. 11) This urge to move is associated with rest, worsens in the evening and is relieved by movement such as stretching or walking. 12) RLS patients are more likely to take longer to fall asleep, have more fragmented and less restful sleep, wake up early, and have more daytime sleepiness. [11] [12] [13] [14] This condition is more common in pregnant women, 15) the elderly, 16) and patients with chronic kidney disease, 17) iron deficiency, 18) and diabetes. 19) The prevalence of RLS is roughly 3 to 10% of the adult general population [20] [21] [22] and is associated with a risk of CVD. 20, 23) However, the prevalence and prognostic impact of RLS on prognosis in HF patients remain unclear.
We aimed to clarify the clinical significance of RLS on the prognosis of HF patients and the associations between RLS and its clinical characteristics of HF patients (e.g., co-morbidities and cardiac function).
Methods
This was a prospective observational study. We enrolled 338 consecutive patients with HF who were evaluated for RLS at Fukushima Medical University between 2014 and 2015 and divided them into two groups on the basis of the presence of RLS: HF patients with RLS (RLS group, n = 29) and HF patients without RLS (non-RLS group, n = 309). The International Classification of Sleep Disorders, 2nd Edition was used for diagnosing RLS. 11, 12, 24, 25) We asked the patients four questions from the classification, and to determine RLS, all answers had to be positive. The questions were as follows: 'Do you have RESTLESS LEGS IN HEART FAILURE an urge to move your legs due to uncomfortable and unpleasant sensations in the legs?,' 'Does this urge to move or the unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting?,' 'Is this urge to move or are the unpleasant sensations partially or totally relieved by movement such as walking or stretching?,' 'Does this urge to move or do the unpleasant sensations worsen in the evening or night compared to during the day, or do they only occur in the evening or night?.' 11, 12, 24, 25) In addition, we have evaluated several co-morbidities of HF, which are associated with prognosis and often coexist with RLS. Hypertension was defined as the recent use of antihypertensive drugs, systolic blood pressure ! 140 mmHg, and/or diastolic blood pressure !90 mmHg. Diabetes mellitus was defined as the recent use of antidiabetic dugs, fasting glucose value !126 mg/dL, casual glucose value !200 mg/dL, and/or HbA1c !6.5% (National Glycohemoglobin Standardization Program). Dyslipidemia was defined as the recent use of cholesterol-lowering drugs, a triglyceride value !150 mg/dL, a low-density lipoprotein cholesterol value !140 mg/dL, and/or a highdensity lipoprotein cholesterol value < 40 mg/dL. Chronic kidney disease was defined as an estimated glomerular filtration rate < 60 mL/minute/1.73 cm 2 according to the Modification of Diet in the Renal Disease formula. 26) Anemia was defined as hemoglobin levels < 12.0 g/dL in females and < 13.0 g/dL in males. 27) Atrial fibrillation was identified by an electrocardiogram performed during hospitalization and/or from medical records.
We compared the clinical features, parameters of laboratory data and echocardiography, and post-discharge prognosis between the RLS and non-RLS groups. The patients were followed until 2018 for cardiac events. Fortunately, we were able to follow-up all patients. A cardiac event was defined as worsened HF and cardiac death. Cardiac death was defined as acute coronary syndrome and worsened HF in accordance with the Framingham criteria, ventricular fibrillation documented by electrocardiogram or implantable devices and determined by independent experienced cardiologists. Status and date of death were obtained from the patients' medical records. If these data were unavailable, status was ascertained by a telephone call to the patient's referring hospital physician. Those administering the survey were blind to the analyses, and written informed consent was obtained from all study subjects. The study protocol was approved by the ethical committee of Fukushima Medical University (number 823); the investigation conforms to the principles outlined in the Declaration of Helsinki; and reporting of the study conforms to STROBE along with references to STROBE and the broader EQUATOR guidelines. 28) Measurement of laboratory data and echocardiographic parameters: Blood samples were obtained from all 338 patients at Fukushima Medical University Hospital at hospital discharge. B-type natriuretic peptide (BNP) levels were measured using a specific immunoradiometric assay (Shionoria BNP kit, Shionogi, Osaka, Japan). High sensitivity cardiac troponin I levels were measured in EDTA anticoagulated plasma using the refined assay (Abbott-Architect, Abbott Laboratories, Abbott Park, IL, USA). Echocardiography was performed blindly by experienced echocardiographers using standard techniques. 29) The left ventricular ejection fraction (LVEF) was calculated using Simpson's method in the four-chamber view. The right ventricular fractional area change (RV-FAC), defined as (end diastolic area − end systolic area) / end diastolic area, was used as a measurement of right ventricular systolic function. All measurements were performed using ultrasound systems (ACUSON Sequoia, Siemens Medical Solutions USA, Inc., Mountain View, CA, USA). Statistical analysis: Categorical variables are expressed as numbers and percentages. A chi-squared test was used for comparisons of categorical variables. Normality was confirmed using the Shapiro-Wilk test in each group. Parametric variables are presented as mean ± SD, and nonparametric variables (e.g., BNP, troponin I and C-reactive protein) are presented as the median and the interquartile range. Parametric variables were compared using Student's t-test, and non-parametric variables were compared using Mann-Whitney's U test. A logistic regression analysis was used to clarify the clinical background associated with prevalence of RLS. A Kaplan-Meier analysis was used for presenting the cardiac event rate, and the logrank test was used for initial comparisons. The prognostic value was tested by a Cox proportional hazard analysis. The proportional hazards assumption for the model was checked by examining log minus-log transformed data. Kaplan-Meier estimates of the survival curves were plotted against time to the follow-up period. These curves helped in identifying non-proportionality patterns in the hazard function such as convergence (difference in risk among the groups decreases with time), divergence, or crossing of the curves. In addition, a Schoenfeld test for the violation of proportional hazards, which can be used to assess the correlation between scaled residuals and time, was also conducted. To assess potential heterogeneity of associations between RLS and the cardiac event rate, since several confounding factors have multicollinearity (e.g., chronic kidney disease and anemia and LVEF and inotropic agents), we conducted a univariate Cox proportional hazard analysis with subgroup analyses, not a multivariate Cox proportional hazard analysis. Interactions between RLS and clinically relevant variables, which are generally known to affect RLS and prognosis in HF patients, were estimated by the Cox proportional hazards regression model. The variables include age, sex, body mass index, New York Heart Association functional class, systolic blood pressure, heart rate, the presence of ischemic etiology, hypertension, diabetes, dyslipidemia, chronic kidney disease, anemia, atrial fibrillation, stroke, alcohol habits, and smoking habits, the use of reninangiotensin system inhibitors, beta blockers, diuretics, and inotropic agents, BNP, troponin I, iron, total protein, albumin, sodium, C-reactive protein, LVEF and RV-FAC. A P value < 0.05 was considered statistically significant for all comparisons. All analyses were performed using a statistical software package (SPSS ver. 24.0, IBM, Armonk, NY, USA). 
Results
Of all 338 HF patients, 29 (8.6%) were categorized into the RLS group, and the comparisons of clinical features between the RLS and non-RLS groups are presented in Table I . Although the prevalence of anemia was significantly higher and chronic kidney disease tended to be higher in the RLS group than in the non-RLS group, we found no significant difference in age, sex, body mass index, the prevalence of ischemic etiology, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, and stroke, or alcohol and smoking habits between the two groups. Regarding medications, the usage of inotropic agents was more frequent in the RLS group than in the non-RLS group, whereas the usage of other medications did not differ between the two groups. In the parameters of laboratory data and echocardiography (Table I) , BNP was significantly higher in the RLS group than in the non-RLS group. In contrast, other laboratory data including troponin I, iron, ferritin, sodium, and C-reactive pro-tein were comparable between the groups. Additionally, both LVEF and RV-FAC were significantly lower in the RLS group than in the non-RLS group. Table II presents the results of the univariable and multivariable logistic regression analyses for presence of RLS. Among the possible confounding factors, anemia was independently associated with the presence of RLS (odds ratio: 3.681, 95% confidence interval: 1.330-10.186, P = 0.012).
During the follow-up period (mean: 423 ± 246 days, range: 21-854 days), there were 125 cardiac events (15 in the RLS group and 110 in the non-RLS group), including 47 cardiac deaths (5 in the RLS group and 42 in the non-RLS group) and 78 cases of worsening HF (10 in the RLS group and 68 in the non-RLS group). As illustrated in the Figure, the cardiac event rate was significantly higher in the RLS group than in the non-RLS group (logrank, P = 0.034). In the Cox proportional hazard analysis (Table III) (Table III) .
Discussion
In the present study, we first demonstrated that 8.6% of HF patients had RLS, and that HF patients with RLS had a higher prevalence of anemia, higher levels of BNP, impaired cardiac function of the right and left ventricles. In addition, presence of RLS was especially affected by anemia and associated with adverse prognosis. RLS may be a potential marker for predicting adverse prognosis. Our findings provide novel insights into RLS in patients with HF.
The mechanisms linking RLS and adverse prognosis in patients with HF remain to be elucidated. RLS could produce CVD through autonomic changes observed with RLS or through other influences on sleep duration or quality. In addition, RLS could promote sympathetic arousal and sympathetic overactivity, activate the hypothalamic-pituitary-adrenal axis and increase the levels of pro-inflammatory cytokines and circulating catecholamine, 20, 30, 31) and all conditions leads to adverse prognosis of HF. Furthermore, RLS is associated with sleep fragmentation and recurrent increases in blood pressure and heart rate that may trigger a non-dipper pattern of blood pressure. 30, 32) By contrast, CVD could produce RLS YOSHIHISA, ET AL through vascular changes in the central nervous system or in the periphery or through the influence of medications (e.g., inotropic agents) for CVD. Thus, presence of RLS may present severity of CVD or HF. In addition, RLSassociated factors (e.g., anemia, iron deficiency, and chronic kidney disease) might partly affect adverse prognosis in HF patients. Sleep disturbance is accompanied by chronic activation of stress responses with increased activity in the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system leading to increased secretion of cortisol and up-regulation of the renin-angiotensin-aldosterone system. 9, 33, 34) Stress response caused by sleep disturbance is also accompanied by increased heart rate, decreased heart rate variability, increased blood pressure, secretion of proinflammatory cytokines and catecholamines, and impaired exercise capacity and activity, 9, 35) which are risk factors for the progression and prognostic factors of HF. These risk factors may in turn contribute to endothelial dysfunction, atherosclerosis, renal dysfunction, and impaired cardiac function. Moreover, these abnormalities may represent a biologically plausible causal link between RLS and HF.
RLS is evaluated by interview, whereas periodic leg movements of sleep (PLMS), brief movements of the lower extremities, are evaluated by polysomnography. Roughly 80% of those with RLS have PLMS. 20) Several studies have been reported on associations between PLMS and CVD. There is a physiological plausibility of the argument that PLMS increases the risk of CVD by increasing sympathetic nervous activity resulting in hypertension, left ventricular hypertrophy, 36) arrhythmia, 37) coronary artery disease, 38) peripheral artery disease, 38) and HF. 36) The pathophysiological mechanism of PLMS appears to be related to a complex neurologic process involving the dopaminergic system with origins in the brain stem and spinal cord leading to increased autonomic and motor activity. 24, 39) In HF patients, the pathophysiology of PLMS is not well understood; however, several factors associated with HF may contribute to its development, such as increased sympathetic nervous activity and inflammation and reduced peripheral blood flow due to HF. 38, 40) The repetitive occurrence of sympathovagal response caused by PLMS may contribute to cardiovascular risk through altering vascular tone, endothelial integrity, and/or triggering arrhythmias. 37) There is an association between PLMS and arrhythmias in not all older men but in subsets of men with HF or myocardial infarction. 37) Concordant with this present analysis, only a few studies reported that PLMS is associated with adverse prognosis in HF patients. [41] [42] [43] The clinical significance of PLMS and its relationship to CVD and HF still remains controversial. 24, [36] [37] [38] The present study suggests that RLS itself may be associated with adverse outcomes in HF patients or that presence of symptom of RLS, which is affected by anemia and impaired cardiac function, can be a potential marker for risk-stratification of HF patients. Study strengths and limitations: There were several limitations in the present study. First, the number of subjects was relatively small. Second, since RLS was diagnosed based on subjective questionnaires, objective evalu-ation was not performed. Third, if confounders were considered in the subgroup analysis, the effects of the differences in co-morbidities between the two groups may not have been completely adjusted. However, we would like to present that HF patients with RLS experience an adverse prognosis, not independent from other underlying differences in clinical backgrounds and parameters but accompanied by anemia and impaired cardiac function in the present study. Fourth, our results do not establish a cause-effect relationship between the presence of RLS and adverse prognosis in HF patients. Thus, the results of the present study should be viewed as preliminary, and further studies with a larger population are required.
Conclusion
RLS was associated with anemia and adverse prognosis in patients with HF. RLS may be a potential marker for predicting adverse prognosis.
